drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous/allogeneic T cells engineered with a lentiviral vector to express a CAR targeting Epstein-Barr virus GP350; IV dose-escalated infusion; designed for MHC-independent killing of GP350-expressing EBV-associated malignant cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally engineered to express a CAR that binds EBV GP350 on EBV-associated malignant cells, enabling MHC-independent recognition and activation of T-cell cytotoxicity (perforin/granzyme release) and cytokine-mediated tumor cell killing.
drug_name
EBV GP350-directed CAR T cells
nct_id_drug_ref
NCT06849921